XML 188 R131.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net deferred tax position - Summary of Net Deferred Tax Position (Details) - EUR (€)
€ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) € 5,801 € 4,570 € 3,540
Deferred tax liabilities 2,166 1,857 1,841
Reserves likely to be distributed in the foreseeable future 64,900    
Deferred tax assets 7,967 6,427 5,381
Consolidation adjustments (intragroup margin in inventory)      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) 1,927 1,525 1,388
Provision for pensions and other employee benefits      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) 787 853 850
Remeasurement of other acquired intangible assets      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) (2,079) [1] (2,795) (3,269)
Remeasurement of other acquired intangible assets | Bioverativ(c)      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Deferred tax liabilities 987    
Remeasurement of other acquired intangible assets | Principia      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Deferred tax liabilities 648    
Remeasurement of other acquired intangible assets | Genzyme      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Deferred tax liabilities 15    
Remeasurement of other acquired intangible assets | Ablynx NV      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Deferred tax liabilities 178    
Recognition of acquired property, plant and equipment at fair value      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) (10) (21) (24)
Equity interests in subsidiaries and investments in other entities      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) [2] (1,044) (1,023) (617)
Tax losses available for carry-forward      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) 971 1,526 1,506
Stock options and other share-based payments      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) 103 84 92
Accrued expenses and provisions deductible at time of payments      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) [3] 2,277 1,994 1,859
Other      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Net deferred tax asset/(liability) [4] 2,869 2,427 1,755
Deferred tax relating to restructuring provisions      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Deferred tax assets 319 286 256
Deferred tax relating to capitalisation of R&D expenses      
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]      
Deferred tax assets € 2,053 € 1,331 € 742
[1] (a)As of December 31, 2024, includes remeasurements of the acquired intangible assets of Bioverativ (€987 million), Principia (€648 million), Ablynx
(€178 million) and Genzyme (€15 million).
[2] (b)In some countries, Sanofi is liable for withholding taxes and other tax charges when dividends are distributed. Consequently, Sanofi recognizes a
deferred tax liability on the reserves of French and foreign subsidiaries (approximately €64.9 billion) which it regards as likely to be distributed in the
foreseeable future. In determining the amount of the deferred tax liability as of December 31, 2024, Sanofi took into account changes in the ownership
structure of certain subsidiaries, and the effects of changes in the taxation of dividends in France, following the ruling of the Court of Justice of
the European Union in the Steria case and the resulting amendments to the 2015 Finance Act. As of December 31, 2023, this line includes a deferred tax
liability arising from temporary differences on investments in subsidiaries which Sanofi expects will reverse in connection with the proposed separation
of the Opella business, as announced in October 2023 (see Note D.30.).
[3] (c)Includes deferred tax assets related to restructuring provisions, amounting to €319 million as of December 31, 2024, €286 million as of December 31,
2023, and €256 million as of December 31, 2022.
[4] (d)Includes deferred taxes arising on the spread tax deduction of R&D expenses, amounting to €2,053 million as of December 31, 2024, €1,331 million as of
December 31, 2023, and €742 million as of December 31, 2022.